PMID- 18305058
OWN - NLM
STAT- MEDLINE
DCOM- 20080515
LR  - 20211203
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 13
IP  - 2
DP  - 2008 Feb
TI  - The potential role of mTOR inhibitors in non-small cell lung cancer.
PG  - 139-47
LID - 10.1634/theoncologist.2007-0171 [doi]
AB  - The mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a 
      downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, 
      which plays a critical role in regulating basic cellular functions including 
      cellular growth and proliferation. Currently, the mTOR inhibitor rapamycin and 
      its analogues (CCI-779, RAD001, AP23573), which induce cell-cycle arrest in the 
      G(1) phase, are being evaluated in cancer clinical trials. The mTOR inhibitors 
      appear to be well tolerated, with skin reactions, stomatitis, myelosuppression, 
      and metabolic abnormalities the most common toxicities seen. These adverse events 
      are transient and reversible with interruption of dosing. Several pieces of 
      evidence suggest a certain antitumor activity, including tumor regressions and 
      prolonged stable disease, which has been reported among patients with a variety 
      of malignancies, including non-small cell lung cancer (NSCLC). These promising 
      preliminary clinical data have stimulated further research in this setting. Here, 
      we review the basic structure of the pathway together with current results and 
      future developments of mTOR inhibitors in the treatment of NSCLC patients.
FAU - Gridelli, Cesare
AU  - Gridelli C
AD  - Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, 83100 
      Avellino, Italy. cgridelli@libero.it
FAU - Maione, Paolo
AU  - Maione P
FAU - Rossi, Antonio
AU  - Rossi A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 48Z35KB15K (ridaforolimus)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Clinical Trials as Topic
MH  - Disease Progression
MH  - ErbB Receptors/drug effects
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology/*therapeutic use
MH  - Lung Neoplasms/*drug therapy
MH  - Protein Kinases/*drug effects/metabolism
MH  - Sirolimus/analogs & derivatives/pharmacology/*therapeutic use
MH  - TOR Serine-Threonine Kinases
MH  - Treatment Outcome
RF  - 74
EDAT- 2008/02/29 09:00
MHDA- 2008/05/16 09:00
CRDT- 2008/02/29 09:00
PHST- 2008/02/29 09:00 [pubmed]
PHST- 2008/05/16 09:00 [medline]
PHST- 2008/02/29 09:00 [entrez]
AID - 13/2/139 [pii]
AID - 10.1634/theoncologist.2007-0171 [doi]
PST - ppublish
SO  - Oncologist. 2008 Feb;13(2):139-47. doi: 10.1634/theoncologist.2007-0171.